Universe Pharmaceuticals Inc. (Class A) (UPC) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, UPC carries an RQD Score of 33, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows:

• Fundamental Cash Engine: 9 / 20 (ROIC 0%; FCF yield 0%). Per the market data, return on invested capital and free-cash-flow yield are both reported at 0%. Per the SEC financials, FY 2025 free cash flow was $-5319.1M, and FY 2024 was $-9715.0M. Only FY 2023 showed positive free cash flow ($1116.8M). This pillar reflects an absence of cash generation in the most recent reported periods.
• Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the lowest-scoring pillar. Per the holders section, no institutional holder data is available, so the score reflects weak or absent institutional support as recorded in the rating.
• Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). Per the holders section, no insider or Congressional trade data is available. The low score reflects the absence of supportive insider flow signals.
• Macro Regime Fit: 8 / 20 (beta 1.0; sector sensitivity). Per the market data, beta is 1.0, meaning the stock is recorded as moving in line with the broader market. The score indicates limited favorable regime alignment.
• Forensic Balance Sheet: 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Per the rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, both weak readings. A Debt/Equity of 0.5 is reported, but cash and debt line items are not available in the financials.

Investor implications: The composite score points to weak fundamentals, weak institutional and insider support, and a forensic profile that the rating classifies as elevated risk. Upside drivers are not evident in the source data; the stock's price of $1.54 sits far below its 52-week high of $17.96, and the 52-week low is $1.45, with a single-session change of -20.21%. Any valuation discussion is constrained because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data. The rating itself is a risk-weighted assessment and is presented here for educational purposes, not as personalized advice.

Universe Pharmaceuticals Inc. (Class A) is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company's market capitalization is $0.0B. The source data does not describe its products, customers, or revenue model. Per the market data, gross margin is 35.3%, indicating that some revenue is retained after direct costs, but the source data does not explain how the company earns that revenue.

Per the SEC financials, revenue declined from $32308.7M (FY 2023) to $23024.5M (FY 2024) and $17858.7M (FY 2025), while the company reported net losses in all three periods. Per the market data, operating margin is -16.3% and net margin is -20.6%. Per the rating, ROIC is 0%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2 out of 9. Balance-sheet posture cannot be fully assessed because cash and debt values are reported as N/A in the financials; the Debt/Equity ratio of 0.5 is the only leverage figure available.

The news feed contains four items, all classified with a YELLOW light and MARKET WIRE impact label. They are generic market-coverage reports (Moomoo, TradingView, Benzinga) describing UPC's market action, institutional positioning, and fundamental catalysts, without specifying the catalysts themselves. Risk watch items drawn from the data include the -20.21% price change, the trading volume of 980963, and the stock's position near its 52-week low. The Butterfly Supply-Chain Graph reports no proprietary signals or butterfly links.

Per the Butterfly Supply-Chain Graph, supply chain status is "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data. Not available in source data for specific dependency mapping.

• What products or revenue streams generate the $17858.7M in FY 2025 revenue, and why did revenue decline in each reported period?
• What are the company's cash and debt balances, given that the financials report both as N/A?
• What is the basis for the market capitalization of $7.7M against FY 2025 revenue of $17858.7M, and what explains the 52-week price decline from $17.96 to $1.54?
• What specific catalysts are referenced in the news feed, since the four items contain only generic coverage descriptions?
• Why are EPS, P/E, and EV/EBITDA unavailable, and what would those metrics show if reported?